Sign Out
TAZATRED (dasatinib) is indicated for the treatment of adults aged 18 years and over with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib. The effectiveness of TAZATRED is based on hematologic and cytogenetic response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease‑related symptoms or increased survival.
TAZATRED is also indicated for the treatment of adults aged 18 years and over with Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Continue with Google